Targeting the Th17 pathway in psoriasis

Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes

(2014) J. Pene et al.   JOURNAL OF IMMUNOLOGY

Identification of SR2211: A Potent Synthetic RORγ-Selective Modulator

(2012) Naresh Kumar et al.   ACS Chemical Biology

Incyte comes of age with JAK inhibitor approval

(2012) Nuala Moran   NATURE BIOTECHNOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psoriasis

(2011) Gayathri K. Perera et al.   Annual Review of Pathology-Mechanisms of Disease

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Brief Report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis

(2011) Sarah Krausz et al.   ARTHRITIS AND RHEUMATISM

Briakinumab for the Treatment of Plaque Psoriasis

(2011) Pawel Traczewski et al.   BIODRUGS

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective

(2011) A. Tefferi et al.   BLOOD REVIEWS

Mouse T helper 17 phenotype: Not so different than in man after all

(2011) Francesco Annunziato et al.   CYTOKINE

Calcipotriol/Betamethasone Dipropionate

(2011) Paul L. McCormack   DRUGS

Dynamics and non-canonical aspects of JAK/STAT signalling

(2011) Anne Mohr et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor E

(2011) Seon Hee Chang et al.   IMMUNITY

Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation

(2011) Yihua Cai et al.   IMMUNITY

Ursolic Acid Suppresses Interleukin-17 (IL-17) Production by Selectively Antagonizing the Function of RORγt Protein

(2011) Tao Xu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo

(2011) M. Ishizaki et al.   JOURNAL OF IMMUNOLOGY

Distinct Roles of IL-23 and IL-17 in the Development of Psoriasis-Like Lesions in a Mouse Model

(2011) Kimiko Nakajima et al.   JOURNAL OF IMMUNOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

(2011) Jordan S. Fridman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

1,25-Dihydroxyvitamin D3 Ameliorates Th17 Autoimmunity via Transcriptional Modulation of Interleukin-17A

(2011) S. Joshi et al.   MOLECULAR AND CELLULAR BIOLOGY

Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity

(2011) Jun R. Huh et al.   NATURE

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand

(2011) Laura A. Solt et al.   NATURE

IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens

(2011) Xinyang Song et al.   NATURE IMMUNOLOGY

Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)

(2011) Dongxu Sun et al.   NATURE IMMUNOLOGY

IL-17C regulates the innate immune function of epithelial cells in an autocrine manner

(2011) Vladimir Ramirez-Carrozzi et al.   NATURE IMMUNOLOGY

The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation

(2011) Katarzyna Bulek et al.   NATURE IMMUNOLOGY

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

(2011) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity

(2011) A. Puel et al.   SCIENCE

T helper 17 cell heterogeneity and pathogenicity in autoimmune disease

(2011) Kamran Ghoreschi et al.   TRENDS IN IMMUNOLOGY

4SC-101, A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor, Suppresses Systemic Lupus Erythematosus in MRL-(Fas)lpr Mice

(2010) Onkar P. Kulkarni et al.   AMERICAN JOURNAL OF PATHOLOGY

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

(2010) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

(2010) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics

(2010) Laura A Solt et al.   CURRENT OPINION IN LIPIDOLOGY

1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells

(2010) Utako Ikeda et al.   IMMUNOLOGY LETTERS

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease†

(2010) Leo R. Fitzpatrick et al.   INFLAMMATORY BOWEL DISEASES

Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis

(2010) G. Tonel et al.   JOURNAL OF IMMUNOLOGY

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A

(2010) H. L. Rizzo et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium

(2010) A. J. Hueber et al.   JOURNAL OF IMMUNOLOGY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis

(2010) Pieter C. M. Res et al.   PLoS One

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

(2009) C. Johansen et al.   BRITISH JOURNAL OF DERMATOLOGY

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease

(2009) S. Brand   GUT

Differential Roles of Interleukin-17A and -17F in Host Defense against Mucoepithelial Bacterial Infection and Allergic Responses

(2009) Harumichi Ishigame et al.   IMMUNITY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease

(2009) Bruce E. Sands et al.   INFLAMMATORY BOWEL DISEASES

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

(2009) L. van der Fits et al.   JOURNAL OF IMMUNOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

(2009) Erin G. Harper et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis

(2009) Shinji Kagami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines

(2009) Consuelo Ortega et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo

(2009) Mandy J McGeachy et al.   NATURE IMMUNOLOGY

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ

(2008) Xuexian O. Yang et al.   IMMUNITY

Foxp3 Inhibits RORγt-mediatedIL-17AmRNA Transcription through Direct Interaction with RORγt

(2008) Kenji Ichiyama et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of inflammatory responses by IL-17F

(2008) Xuexian O. Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Deficiency of Th17 cells in hyper IgE syndrome due to mutations inSTAT3

(2008) Cindy S. Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells

(2008) Lisa C. Zaba et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis?

(2007) Erik Lubberts   CYTOKINE